Decline in Selling Prices Due to Intensifying Competition and Technological Innovation
First written in FY2017. 1 of 2 entries say "Materialised", first in FY2018. Latest entry: FY2018.
Terumo moved to the "Worse" side of this theme in 2018, 2 years before the typical company in this theme (2020).
The whole theme swung hardest in 2020: 4 of 11 companies on the "Worse" side.
2 other companies' latest entry also says "Materialised".
- FY2018MaterialisedAnnual report
「In Japan, sales of infusion systems, which are expected to improve treatment safety and operational efficiency, analgesics intended to relieve pain, and sprayable adhesion barriers used to reduce postoperative adhesions remained firm. However, revenue declined due to intensifying competition in commodity products such as syringes and in infusion solutions.」
Intensifying competition actually emerged as a factor behind declining revenue from commodity products such as syringes and infusion solutions. - FY2017First statedAnnual report
「In Japan and overseas, intensified competition among companies in the market and technological innovation may lead to significant price declines, and fluctuations in these selling prices may affect our operating results and financial condition.」
The risk of significant selling price declines due to competition among companies and technological innovation was disclosed independently for the first time, separately from reimbursement price revisions by health authorities.